Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ionis Pharmaceuticals Inc

NASDAQ: IONS · Life Sciences · 7 alerts · CIK 874015

Ionis Pharmaceuticals Inc stories on ALFA USA NewsRead the news →
Share price
$28.01Close, Nov 16
Market cap
$4.66B
Shares outstanding
166.55MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ionis Pharmaceuticals Inc filings on SEC EDGAR ↗

1:42 PM ET 8-K
Clinical Trial Data

Ionis Pharmaceuticals Clinical Trial Data

Ionis Pharmaceuticals and its partner Roche announced positive Phase 3 IMAgINATION study results for sefaxersen in patients with IgA nephropathy. The trial met its primary endpoint, demonstrating a statistically significant 43.1% reduction in proteinuria compared to placebo at 37 weeks, with a safety profile consistent with earlier studies.

Counterparty
Roche

“These data support our belief that sefaxersen is uniquely positioned to treat IgA nephropathy, demonstrating significant and clinically meaningful reduction in proteinuria and offering the potential to help reduce the need for long-term dialysis or kidney transplantation.”

Brett P. Monia, Ph.D., chief executive officer, Ionis

“Sefaxersen is a powerful example of the broad impact of Ionis' innovative science, and based on these positive data, we believe it has the potential to be an important new treatment option for people living with IgA nephropathy.”

Brett P. Monia, Ph.D., chief executive officer, Ionis
6:03 AM ET 8-K
Clinical Trial Data

Ionis Pharmaceuticals Clinical Trial Data

Ionis and partner Roche announced positive interim results from the Phase 3 IMAgINATION study of sefaxersen in adults with IgA nephropathy (IgAN). The study met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in proteinuria compared to placebo at 37 weeks.

Counterparty
Roche Holding Ltd.

“With these positive interim results, sefaxersen is positioned to directly address a primary driver of IgAN-related kidney damage, offering the potential to help slow disease progression and potentially reduce the long-term need for dialysis or kidney transplantation.”

Brett P. Monia, Ph.D., chief executive officer, Ionis

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.